MXPA03001210A - Uso de antagonista del receptor 5-ht4 en la fabricacion de un medicamento para la profilaxis o tratamiento de fibrilacion atrial. - Google Patents

Uso de antagonista del receptor 5-ht4 en la fabricacion de un medicamento para la profilaxis o tratamiento de fibrilacion atrial.

Info

Publication number
MXPA03001210A
MXPA03001210A MXPA03001210A MXPA03001210A MXPA03001210A MX PA03001210 A MXPA03001210 A MX PA03001210A MX PA03001210 A MXPA03001210 A MX PA03001210A MX PA03001210 A MXPA03001210 A MX PA03001210A MX PA03001210 A MXPA03001210 A MX PA03001210A
Authority
MX
Mexico
Prior art keywords
prophylaxis
treatment
mammal
salt
pharmaceutically acceptable
Prior art date
Application number
MXPA03001210A
Other languages
English (en)
Inventor
Bela Rajiv Patel
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0019410A external-priority patent/GB0019410D0/en
Priority claimed from GB0019524A external-priority patent/GB0019524D0/en
Priority claimed from GB0019523A external-priority patent/GB0019523D0/en
Priority claimed from GB0118919A external-priority patent/GB0118919D0/en
Priority claimed from GB0119022A external-priority patent/GB0119022D0/en
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of MXPA03001210A publication Critical patent/MXPA03001210A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invencion se refiere al uso de un antagonista del receptor de 5-HT4 en la elaboracion de un medicamento para la profilaxis o tratamiento de remodelamiento atrial en un mamifero; preferiblemente, el antagonista es N-[(1-nbutil -4-piperidiniI) metil] -3, 4-dihidro-2H -[1, 3]oxazino [3, 2-1]indol- 10- carboxamida (SB 207266) o una sal farmaceuticamente aceptable de la misma; la invencion tambien se refiere al uso de SB 207266 o una sal farmaceuticamente aceptable de la misma en la elaboracion de un medicamento para el tratamiento o profilaxis de la fibrilacion atrial en un mamifero mediante la administracion al mamifero de un regimen de dosis diaria oral o parenteral de aproximadamente 0.2 mg a 1.0 mg de la SB 207266 o la sal de la misma por kg de peso corporal total (medida como la base libre); la invencion tambien se refiere al uso de SB 207266 o una sal farmaceuticamente aceptable de la misma en la profilaxis o tratamiento de arritmia atrial en un mamifero mediante la administracion de la SB 207266 o la sal de la misma en el primer dia a una dosis de carga de aproximadamente 1.2 a aproximadamente 2.0 veces la dosis diaria de mantenimiento, seguida por la administracion de la SB 207266 o sal a la dosis diaria de mantenimiento en dias subsecuentes.
MXPA03001210A 2000-08-07 2001-08-07 Uso de antagonista del receptor 5-ht4 en la fabricacion de un medicamento para la profilaxis o tratamiento de fibrilacion atrial. MXPA03001210A (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GB0019410A GB0019410D0 (en) 2000-08-07 2000-08-07 Novel use
GB0019524A GB0019524D0 (en) 2000-08-08 2000-08-08 Novel use
GB0019523A GB0019523D0 (en) 2000-08-08 2000-08-08 Novel use
GB0118919A GB0118919D0 (en) 2001-08-02 2001-08-02 Novel use
GB0119022A GB0119022D0 (en) 2001-08-03 2001-08-03 Novel use
PCT/GB2001/003544 WO2002011766A2 (en) 2000-08-07 2001-08-07 Use of 5ht4 receptor antagonists in the manufacture of a medicament for the prophylaxis or treatment of atrial fibrillation

Publications (1)

Publication Number Publication Date
MXPA03001210A true MXPA03001210A (es) 2004-08-12

Family

ID=27515972

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA03001210A MXPA03001210A (es) 2000-08-07 2001-08-07 Uso de antagonista del receptor 5-ht4 en la fabricacion de un medicamento para la profilaxis o tratamiento de fibrilacion atrial.

Country Status (16)

Country Link
US (3) US20050032866A1 (es)
EP (1) EP1311295A2 (es)
JP (2) JP2004505930A (es)
KR (1) KR20030027010A (es)
CN (1) CN100413539C (es)
AU (1) AU781276B2 (es)
BR (1) BR0113073A (es)
CA (1) CA2418904A1 (es)
CZ (1) CZ2003366A3 (es)
HU (1) HUP0303075A3 (es)
IL (1) IL154279A0 (es)
MX (1) MXPA03001210A (es)
NO (1) NO20030588L (es)
NZ (1) NZ524108A (es)
PL (1) PL365048A1 (es)
WO (1) WO2002011766A2 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005523276A (ja) * 2002-02-14 2005-08-04 グラクソ　グループ　リミテッド Ｎ−［（１−ｎ−ブチル−４−ピペリジニル）メチル］−３，４−ジヒドロ−２ｈ−［１，３］オキサジノ［３，２−ａ］インドール−１０−カルボキシアミド（ｓｂ２０７２６６）またはその塩および乾燥造粒操作を含む方法
GB0211230D0 (en) 2002-05-16 2002-06-26 Medinnova Sf Treatment of heart failure
EP2366431A1 (en) * 2010-03-19 2011-09-21 Universitätsklinikum Hamburg-Eppendorf Myeloperoxidase as a target in atrial fibrillation
AU2015297705B2 (en) 2014-07-30 2019-12-19 Aetas Pharma Co., Ltd. Optical isomer of 1,4-benzothiazepine-1-oxide derivative, and pharmaceutical composition prepared using same

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9009389D0 (en) * 1990-04-26 1990-06-20 Smith Kline French Lab Treatment
GB9103862D0 (en) * 1991-02-25 1991-04-10 Glaxo Group Ltd Chemical compounds
DK0604494T3 (da) * 1991-09-12 1999-11-29 Smithkline Beecham Plc 5-HT4-receptorantagonister
MA22647A1 (fr) * 1991-09-14 1993-04-01 Smithkline Beecham Plc Procede de preparation d'un ester ou d'un amide d'un nouveau produit .
HU219121B (hu) * 1992-03-12 2001-02-28 Smithkline Beecham Plc. Kondenzált indolszármazékok, eljárás előállításukra és ezeket tartalmazó 5-HT4-receptor antagonista hatású gyógyászati készítmények
US5998409A (en) * 1992-03-12 1999-12-07 Smithkline Beecham Plc Condensed indole derivatives as 5HT4 -receptor antagonists
US5852014A (en) * 1992-03-12 1998-12-22 Smithkline Beecham P.L.C. Condensed indole derivatives as 5HT4 -receptor antagonists
IL105232A0 (en) * 1992-03-31 1993-07-08 Glaxo Group Ltd Substituted phenylcarbamates and ureas,their preparation and pharmaceutical compositions containing them
ATE188697T1 (de) * 1992-03-31 2000-01-15 Glaxo Group Ltd Substituierte phenylcarbamate und phenylharnstoffe, ihre herstellung und ihre verwendung als 5-ht4-antagonisten
GB9206989D0 (en) * 1992-03-31 1992-05-13 Glaxo Group Ltd Chemical compounds
NZ267296A (en) * 1993-05-26 1997-04-24 Syntex Inc 4-(aminophenyl) omega amino- or 4-piperidyl- alkyl ketone derivatives; pharmaceutical compositions
IL117438A (en) * 1995-03-16 2001-12-23 Lilly Co Eli Indazolecarboxamides, their preparation and pharmaceutical compositions containing them
DE69703554T2 (de) * 1996-08-16 2001-07-05 Smithkline Beecham Plc VERFAHREN ZUR HERSTELLUNG VON N- (1-n-BUTYL-4-PIPERIDINYL)METHYL] -3,4-DIHYDRO -2H-[1,3]OXAZINO[3,2-a]INDOL-10-CARBOXAMID UND SALZE SOWIE ZWISCHENPRODUKTE IN DEM VERFAHREN
NZ535261A (en) * 2000-08-08 2004-12-24 Smithkline Beecham P A tablet comprising the hydrochloride salt of N-(1-nbutyl-4-piperidinyl)methyl]-3,4-[1,3]oxazino[3,2-a] indole-10-carboxamide

Also Published As

Publication number Publication date
US20070015769A1 (en) 2007-01-18
EP1311295A2 (en) 2003-05-21
NO20030588L (no) 2003-04-03
HUP0303075A3 (en) 2007-03-28
IL154279A0 (en) 2003-09-17
CN1468112A (zh) 2004-01-14
JP2004505930A (ja) 2004-02-26
HUP0303075A2 (hu) 2003-12-29
PL365048A1 (en) 2004-12-27
WO2002011766A2 (en) 2002-02-14
NO20030588D0 (no) 2003-02-06
CA2418904A1 (en) 2002-02-14
NZ524108A (en) 2004-11-26
CN100413539C (zh) 2008-08-27
US20050032866A1 (en) 2005-02-10
JP2007145869A (ja) 2007-06-14
CZ2003366A3 (en) 2004-04-14
WO2002011766A3 (en) 2002-08-01
KR20030027010A (ko) 2003-04-03
AU7652901A (en) 2002-02-18
BR0113073A (pt) 2004-06-22
AU781276B2 (en) 2005-05-12
US20080125422A1 (en) 2008-05-29

Similar Documents

Publication Publication Date Title
Kris et al. Use of an NK1 receptor antagonist to prevent delayed emesis after cisplatin
US20020173505A1 (en) Medicament
RU2005124363A (ru) Твердые пероральные дозируемые формы валсартана
IL149496A (en) Pharmaceutical compositions and their use in the treatment of the gastrointestinal tract
CA2237582C (en) Use of 5ht4 receptor antagonists for overcoming gastrointestinal effects of serotonin reuptake inhibitors
CA2414111A1 (en) Use of substituted indole compounds for increasing nitric oxide synthase activity
WO2002004418A2 (en) Methods of inhibiting uterotrophic effects of estrogenic agents
CA2521182A1 (en) Composition for improving cognition and memory
CA2593854A1 (en) Organic compounds
MXPA03001210A (es) Uso de antagonista del receptor 5-ht4 en la fabricacion de un medicamento para la profilaxis o tratamiento de fibrilacion atrial.
JP2575569B2 (ja) 薬物従属症及び禁断症状の治療に関するグリシン／ｎｍｄａレセプターリガンドの用法
NZ535261A (en) A tablet comprising the hydrochloride salt of N-(1-nbutyl-4-piperidinyl)methyl]-3,4-[1,3]oxazino[3,2-a] indole-10-carboxamide
US6455552B1 (en) Combination of a GABAA α5 inverse agonist and a muscarinic agonist
MY143571A (en) Eplerenone crystalline form
WO2000076500A8 (en) Compound for use as a medicament for treatment of disorders involving bronchocontraction
MY138979A (en) The use of 5ht4 receptor antagonists in the prophylaxis or treatment of certain cardiovascular conditions
EP1061925A1 (en) Combination of a gaba-a alpha 5 inverse agonist and a nicotinic agonist
MXPA01010340A (es) Osanetant en el tratamiento de transtornos del humor.
AU604554B2 (en) Treatment of cardiac arrhythmias
US4122177A (en) Method of treating oligospermia and asthenospermia
GB2173399A (en) Compositions containing 3-aminopropoxy-indoles for treating hypertension
JP2700799B2 (ja) 鎮咳剤
JP2004505930A5 (es)
US4363809A (en) Organic compounds
Westmead Drugs for Parkinson’s disease